Glucagon-like peptide 1--a cardiologic dimension

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Glucagon-like peptide 1--a cardiologic dimension. / Treiman, Marek; Elvekjaer, Mikkel; Engstrøm, Thomas; Jensen, Jan Skov.

I: Trends in Cardiovascular Medicine, Bind 20, Nr. 1, 01.01.2010, s. 8-12.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Treiman, M, Elvekjaer, M, Engstrøm, T & Jensen, JS 2010, 'Glucagon-like peptide 1--a cardiologic dimension', Trends in Cardiovascular Medicine, bind 20, nr. 1, s. 8-12. https://doi.org/10.1016/j.tcm.2010.02.012

APA

Treiman, M., Elvekjaer, M., Engstrøm, T., & Jensen, J. S. (2010). Glucagon-like peptide 1--a cardiologic dimension. Trends in Cardiovascular Medicine, 20(1), 8-12. https://doi.org/10.1016/j.tcm.2010.02.012

Vancouver

Treiman M, Elvekjaer M, Engstrøm T, Jensen JS. Glucagon-like peptide 1--a cardiologic dimension. Trends in Cardiovascular Medicine. 2010 jan. 1;20(1):8-12. https://doi.org/10.1016/j.tcm.2010.02.012

Author

Treiman, Marek ; Elvekjaer, Mikkel ; Engstrøm, Thomas ; Jensen, Jan Skov. / Glucagon-like peptide 1--a cardiologic dimension. I: Trends in Cardiovascular Medicine. 2010 ; Bind 20, Nr. 1. s. 8-12.

Bibtex

@article{73703bd9e57b4fa8bb95188f98168e20,
title = "Glucagon-like peptide 1--a cardiologic dimension",
abstract = "Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.",
keywords = "Animals, Blood Pressure, Cardiovascular Agents, Glucagon-Like Peptide 1, Heart Diseases, Humans, Myocardial Contraction, Myocardial Reperfusion Injury, Signal Transduction, Treatment Outcome, Vasodilation, Ventricular Function, Left",
author = "Marek Treiman and Mikkel Elvekjaer and Thomas Engstr{\o}m and Jensen, {Jan Skov}",
note = "(c) 2010 Elsevier Inc. All rights reserved.",
year = "2010",
month = jan,
day = "1",
doi = "10.1016/j.tcm.2010.02.012",
language = "English",
volume = "20",
pages = "8--12",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide 1--a cardiologic dimension

AU - Treiman, Marek

AU - Elvekjaer, Mikkel

AU - Engstrøm, Thomas

AU - Jensen, Jan Skov

N1 - (c) 2010 Elsevier Inc. All rights reserved.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.

AB - Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.

KW - Animals

KW - Blood Pressure

KW - Cardiovascular Agents

KW - Glucagon-Like Peptide 1

KW - Heart Diseases

KW - Humans

KW - Myocardial Contraction

KW - Myocardial Reperfusion Injury

KW - Signal Transduction

KW - Treatment Outcome

KW - Vasodilation

KW - Ventricular Function, Left

U2 - 10.1016/j.tcm.2010.02.012

DO - 10.1016/j.tcm.2010.02.012

M3 - Journal article

C2 - 20685571

VL - 20

SP - 8

EP - 12

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 1

ER -

ID: 33870091